Apimeds Pharmaceuticals US Inc (APUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | |
| Operating Expenses | 1,275 | 747 |
| Operating Income | -1,275 | -747 |
| Interest Expense | 118 | 38 |
| Other Income | 3 | 8 |
| Pre-tax Income | -1,390 | -778 |
| Net Income Continuous | -1,390 | -778 |
| Net Income | $-1,390 | $-778 |
| EPS Basic Total Ops | -0.18 | -0.17 |
| EPS Basic Continuous Ops | -0.18 | -0.17 |
| EPS Diluted Total Ops | -0.18 | -0.17 |
| EPS Diluted Continuous Ops | -0.18 | -0.17 |
| EPS Diluted Before Non-Recurring Items | -0.18 | N/A |
| EBITDA(a) | $-1,275 | $-747 |